Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis

[1]  A. Italiano,et al.  Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study , 2021, Gynecologic Oncology.

[2]  C. V. van Asperen,et al.  Universal immunohistochemistry for Lynch Syndrome: a systematic review and meta-analysis of 58,580 colorectal carcinomas. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Cyrus Chargari,et al.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.

[4]  M. Kloor,et al.  European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender , 2020, The British journal of surgery.

[5]  D. Evans,et al.  The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study , 2020, PLoS medicine.

[6]  Mark Robson,et al.  Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Z. Zeng,et al.  Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy , 2020, Molecular Cancer.

[8]  P. Neven,et al.  Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. , 2020, Gynecologic oncology.

[9]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Tomlinson,et al.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG) , 2019, Gut.

[11]  D. Jäger,et al.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Xia,et al.  The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis , 2019, Front. Oncol..

[13]  C. Gilks,et al.  Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results , 2019, Histopathology.

[14]  C. Gilks,et al.  Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma , 2019, Histopathology.

[15]  D. Evans,et al.  Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting , 2019, PloS one.

[16]  M. Edelman,et al.  Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors , 2019, Advances in Therapy.

[17]  M. Fassan,et al.  Tumor mutation burden: from comprehensive mutational screening to the clinic , 2019, Cancer Cell International.

[18]  A. Benson,et al.  Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. , 2019, The oncologist.

[19]  A. Scarpa,et al.  ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Luca Mazzarella,et al.  Tumor mutational burden quantification from targeted gene panels: major advancements and challenges , 2019, Journal of Immunotherapy for Cancer.

[21]  P. Glazer,et al.  Impact of hypoxia on DNA repair and genome integrity. , 2019, Mutagenesis.

[22]  K. Tamura,et al.  Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome , 2019, International Journal of Clinical Oncology.

[23]  A. Cavazza,et al.  Experience of the implementation and outcomes of universal testing for Lynch syndrome in the United Kingdom , 2019, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[24]  D. Evans,et al.  The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis , 2019, Genetics in Medicine.

[25]  A. Gill,et al.  Australasian Gastrointestinal Pathology Society (AGPS) consensus guidelines for universal defective mismatch repair testing in colorectal carcinoma. , 2019, Pathology.

[26]  P. Kantoff,et al.  Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade , 2019, JAMA oncology.

[27]  P. Møller,et al.  The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome , 2019, Genetics in Medicine.

[28]  J. Deleuze,et al.  Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer , 2018, Front. Oncol..

[29]  A. Mattia,et al.  Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome , 2018, Cancer.

[30]  W. Frankel,et al.  Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency , 2018, Modern Pathology.

[31]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[32]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[33]  D. Lieberman,et al.  Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-society Task Force on Colorectal Cancer. , 2017, Journal of pediatric gastroenterology and nutrition.

[34]  E. Steyerberg,et al.  Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age. , 2016, Gynecologic oncology.

[35]  H. Morreau,et al.  Practical guidance for mismatch repair-deficiency testing in endometrial cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  R. Chung,et al.  Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan , 2016, PloS one.

[37]  E. Kuipers,et al.  Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age , 2016, Genetics in Medicine.

[38]  P. Georgii‐Hemming,et al.  The gynecological surveillance of women with Lynch syndrome in Sweden. , 2015, Gynecologic oncology.

[39]  K. Al-Kuraya,et al.  Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer , 2015, Cancer.

[40]  I. Frayling,et al.  A model-based assessment of the cost–utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients , 2015, BMC Cancer.

[41]  S. Gruber,et al.  Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. , 2014, JAMA dermatology.

[42]  M. Haasova,et al.  Model-Based Cost-Utility Analysis of Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Treatment Induced Anaemia in the UK NHS. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[43]  Colin C Pritchard,et al.  Microsatellite instability detection by next generation sequencing. , 2014, Clinical chemistry.

[44]  J. Church,et al.  Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer , 2014, The American Journal of Gastroenterology.

[45]  I. Bissett,et al.  Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel. , 2013, The New Zealand medical journal.

[46]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[47]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[48]  M. Ilyas,et al.  Immunostaining for mismatch repair (MMR) protein expression in colorectal cancer is better and easier to interpret when performed on diagnostic biopsies , 2012, Histopathology.

[49]  W. Chow,et al.  Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore , 2012, Familial Cancer.

[50]  C. Boland,et al.  Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer , 2011, Annals of Internal Medicine.

[51]  R. Pai,et al.  A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas , 2011, Modern Pathology.

[52]  R. Yantiss,et al.  Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma , 2010, The American journal of surgical pathology.

[53]  C. Boland,et al.  MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer , 2010, Clinical Cancer Research.

[54]  A. Gill,et al.  Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma , 2010, Pathology.

[55]  Heather Hampel,et al.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer , 2010, Genetics in Medicine.

[56]  Laura H. Tang,et al.  Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.

[57]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[58]  R. Chisin.  Cost-Effectiveness Analysis , 2009, Journal of Nuclear Medicine.

[59]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  W Künzel,et al.  What is new? , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[61]  John D Potter,et al.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. , 2007, Gastroenterology.

[62]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[63]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[64]  D. Schaid,et al.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. , 2001, American journal of human genetics.

[65]  M. Leppert,et al.  The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. , 2001, Gastroenterology.

[66]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[68]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[69]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[70]  A. Duval,et al.  [Lynch syndrome: What is new?] , 2018, Bulletin du cancer.

[71]  M. Ladanyi,et al.  Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency , 2013, Modern Pathology.

[72]  J. Stockman,et al.  Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer: A Cost-Effectiveness Analysis , 2013 .

[73]  Douglas G. Altman,et al.  Explanation and Elaboration , 2022 .